Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized,Multi-center,Parallel-group, Phase II(Single-blind)/Phase III(Double- Blind)Study to Determine the Optimal Dose and to Evaluate the Efficacy and Safety of GCPGC on Chemotherapy-induced Neutropenia Compared to Neulasta(Pegfilgrastim)

NCT01328938 is registered in ClinicalTrials.gov with Green Cross Corporation as lead sponsor.

NCT NCT01328938
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01328938 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized,Multi-center,Parallel-group, Phase II(Single-blind)/Phase III(Double- Blind)Study to Determine the Optimal Dose and to Evaluate the Efficacy and Safety of GCPGC on Chemotherapy-induced Neutropenia Compared to Neulasta(Pegfilgrastim)
Lead sponsor
Green Cross Corporation
Phase
Phase 2/3
Overall status
Completed
Start date
October 31, 2010
Completion date
May 31, 2013
Enrollment
177 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy induced neutropenia